Invivyd (NASDAQ:IVVD) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note issued to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

Invivyd Price Performance

NASDAQ:IVVD opened at $0.85 on Tuesday. The firm has a market capitalization of $101.63 million, a price-to-earnings ratio of -0.46 and a beta of 0.66. Invivyd has a twelve month low of $0.84 and a twelve month high of $5.20. The stock’s 50 day moving average price is $1.10 and its two-hundred day moving average price is $2.18.

Institutional Trading of Invivyd

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Invivyd by 3.9% during the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after acquiring an additional 97,496 shares during the period. Tidal Investments LLC acquired a new position in shares of Invivyd in the 1st quarter worth approximately $126,000. Acadian Asset Management LLC bought a new stake in Invivyd during the first quarter valued at $905,000. Jacobs Levy Equity Management Inc. grew its stake in Invivyd by 21.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock worth $1,933,000 after purchasing an additional 77,603 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Invivyd by 198.6% in the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after acquiring an additional 25,201 shares in the last quarter. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.